ARBITER 6-HALTS (niacin vs ezetimibe) 2009

NCT00397657

1 Treatments

Studied treatment  extended-release niacin 1 g/d, titrated to max tolerable dose up to 2 g/d (HDL-focused strategy)

Control treatment  ezetimibe 10 mg/d (LDL-focused strategy)

Concomittant treatments  -

Male (%)  -

Age (years)  -

2 Patients

Patients  patients with known coronary or vascular disease or coronary risk equivalents

Inclusion criteria  -

Exclusion criteria  -

Diabetes (%)  -

History of CHD  -

3 Methods

Blinding  open

Design  Parallel groups

Centers  2

Geographical area  US

Sizes  97/111
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>coronary death</td>
<td>-/97</td>
<td>-/111</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all-cause death</td>
<td>-/97</td>
<td>-/111</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>HDL</td>
<td>-/97</td>
<td>-/111</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>stroke</td>
<td>-/97</td>
<td>-/111</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiovascular events</td>
<td>282/187</td>
<td>9/176</td>
<td>29.49</td>
<td>[15.39; 56.51]</td>
</tr>
<tr>
<td>major CHD events</td>
<td>2/187</td>
<td>9/176</td>
<td>0.21</td>
<td>[0.04; 0.98]</td>
</tr>
<tr>
<td>cardiovascular deaths</td>
<td>-/97</td>
<td>-/111</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References
